Contributions
Abstract: EP1326
Type: ePoster
Abstract Category: Clinical aspects of MS - 4 Natural course
Objectives: A number of studies have previously described rates of conversion from relapsing remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), and times to the onset of secondary progressive disease. However, a comprehensive review of all the available evidence base has not been undertaken. The objective of this review was to synthesize the evidence on disease progression in MS patients.
Methods: A systematic search was conducted on MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews using the OVID platform to identify the articles reporting clinical course of multiple sclerosis. Studies were included that described risk of, or time to, conversion from RRMS to SPMS, or from relapsing SPMS to non-relapsing SPMS.
Results: In total, 5482 articles were identified and of these, 92 articles reported findings relevant to progression to SPMS. Following an initial relapsing-remitting course, there is a gradual increase in the number of patients converting to SPMS, with around 25% progressing by 10 years, 50% by 20 years, and more than 75% by 30 years. Estimates for the time to SPMS onset had significant variation ranging from 5 to 41.8 years, with most studies reporting a mean age of approximately 40 years at conversion to SPMS. Earlier onset of MS is associated with longer time to secondary progression, but also with conversion at a younger age. Frequent relapses in the relapsing-remitting phase, particularly within the first 2 years, correlate with early progression to SPMS. No studies described conversion from RRMS to relapsing SPMS, or from relapsing SPMS to non-relapsing disease.
Conclusions: Although there are a large number of studies reporting data on progression from RRMS to SPMS but there is significant variation in the reported data. Further studies may be required to understand the transition between RRMS to relapsing SPMS, and from relapsing SPMS to non-relapsing disease.
Disclosure:
Jennie Medin is an employee of Novartis Pharma AG, Basel, Switzerland;
Vivek Khurana is an employee of Novartis Healthcare Private Limited, Hyderabad, India.
Funding: This study was funded by Novartis Pharma AG, Basel, Switzerland
Abstract: EP1326
Type: ePoster
Abstract Category: Clinical aspects of MS - 4 Natural course
Objectives: A number of studies have previously described rates of conversion from relapsing remitting multiple sclerosis (RRMS) to secondary progressive multiple sclerosis (SPMS), and times to the onset of secondary progressive disease. However, a comprehensive review of all the available evidence base has not been undertaken. The objective of this review was to synthesize the evidence on disease progression in MS patients.
Methods: A systematic search was conducted on MEDLINE, EMBASE, and Cochrane Database of Systematic Reviews using the OVID platform to identify the articles reporting clinical course of multiple sclerosis. Studies were included that described risk of, or time to, conversion from RRMS to SPMS, or from relapsing SPMS to non-relapsing SPMS.
Results: In total, 5482 articles were identified and of these, 92 articles reported findings relevant to progression to SPMS. Following an initial relapsing-remitting course, there is a gradual increase in the number of patients converting to SPMS, with around 25% progressing by 10 years, 50% by 20 years, and more than 75% by 30 years. Estimates for the time to SPMS onset had significant variation ranging from 5 to 41.8 years, with most studies reporting a mean age of approximately 40 years at conversion to SPMS. Earlier onset of MS is associated with longer time to secondary progression, but also with conversion at a younger age. Frequent relapses in the relapsing-remitting phase, particularly within the first 2 years, correlate with early progression to SPMS. No studies described conversion from RRMS to relapsing SPMS, or from relapsing SPMS to non-relapsing disease.
Conclusions: Although there are a large number of studies reporting data on progression from RRMS to SPMS but there is significant variation in the reported data. Further studies may be required to understand the transition between RRMS to relapsing SPMS, and from relapsing SPMS to non-relapsing disease.
Disclosure:
Jennie Medin is an employee of Novartis Pharma AG, Basel, Switzerland;
Vivek Khurana is an employee of Novartis Healthcare Private Limited, Hyderabad, India.
Funding: This study was funded by Novartis Pharma AG, Basel, Switzerland